2023 Core Competency Program Bundle (Institutional)

Type: BundleFormat: On-demand

HOPA Core Competency provides fundamental oncology pharmacy education to pharmacists and other healthcare providers who are new to this practice area or who want to refresh their knowledge.


Welcome Core Competency Learners!

If your institution has already purchased this bundle, please click here:

Redeem Your HOPA Core Competency Code

Please note: these courses will expire on June 26, 2026.


Core Competency Institutional Bundle Description  

Instituions of all sizes can purchase licenses to the Core Competency Bundle at discounted rates. If the person placing the order is a member of HOPA, member pricing applies.

Topics include various treatment options, chemotherapy safety, chemotherapy admixture, pharmacology and chemotherapy toxicity, and prevention/management.

Please see below for a list of the 12 modules included in this release.

Upon completion of this program, pharmacists will earn 12.5 continuing pharmacy education credit hours.

Get It Now!


2023 Core Competency Modules

Get it Now!

Please note: these courses will expire on June 26, 2026.

For questions about pricing or to purchase Core Competency for institutions, contact HOPA's Staff at education@hoparx.org or  877-467-2791.


Knowledge Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

All CE hours will be transmitted to the CPE Monitor within 1-2 weeks of course completion. ACPE credit must be claimed by June 26, 2026. 

ACPELOGOrs2

Accreditation Statement

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test. 

Disclosure of Conflicts of Interest

The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.